ClinicalTrials.gg
CompletedNCT06897748COMETAUpdated Jul 14, 2026

A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

A Phase 2 interventional study of Placebo and Tozorakimab in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 12 sites in Russia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
114th of 194
98 · median 137
Started
2025
with 12 others
Phase 2
54 of 284
1 open now
Registered
272nd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 114th largest by enrollment of the 194 interventional ones that give a count, is one of 13 that started in 2025, is one of 54 in phase 2, and was the 272nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or placebo administrations in participants with symptomatic chronic obstructive pulmonary disease (COPD) with history of exacerbations and high blood eosinophil counts.

Study details include the following:

  • The maximum duration of the screening/run-in period is 5 weeks. An additional unscheduled visit may be performed prior to randomization to repeat safety assessments as deemed necessary by the investigator.
  • Eligible patients will enter 12-week treatment (intervention) period with site visits and investigational product (IP) administration every 2 weeks.
  • Participants who complete a treatment period, and have not been prematurely discontinued from IP, will enter a 10-week post-intervention follow-up period.
  • The study duration will be 27 weeks at maximum for each participant.
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • tozorakimab
  • MEDI3506
  • ICS
  • LABA/LAMA
  • Biologic
  • Biologic Treatment
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 40 years of age and capable of giving signed .
  2. Documented diagnosis of for at least one year prior to enrolment.
  3. Post-BD /FVC \< 0.70 and post-BD FEV1 >20% and \< 80% of predicted normal value.
  4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.
  5. Documented optimised inhaled dual or triple therapy for at least 3 months prior to enrolment.
  6. Smoking history of ≥ 10 pack-years.
  7. CAT total score ≥ 10, with each of the phlegm (sputum) and cough items with a score ≥ 2.
  8. All participants must have eosinophil blood count ≥ 150 cells/µL.

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than .
  2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms. Radiological findings of pulmonary nodules suspicious for lung cancer, as per applicable guidances, without appropriate follow up prior to randomisation. Radiological findings suggestive of acute infection.
  3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
  4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.
  5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic and/or antibiotics, and/or led to hospitalization.
  6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.
  7. Significant COVID-19 illness within the 6 months prior to enrolment.
  8. Unstable cardiovascular disorder.
  9. Diagnosis of clinically significant cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.
  10. History of active severe inflammatory bowel disease or colitis within one year prior to enrolment, or unexplained diarrhoea within the 4 weeks prior to randomisation.
  11. History of known immunodeficiency disorder, including a positive test for -1 or HIV 2.
  12. History of positive test or treatment for or (except for cured hepatitis C).
  13. Evidence of active liver disease, including jaundice during screening.
  14. , current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.
  15. Participants who, in the opinion of the Investigator or qualified designee, have evidence of active TB.
  16. History of partial or total lung resection.
  17. Scheduled major surgical procedure during the course of the study.
  18. Participants that have previously received tozorakimab.
  19. Change in smoking status in 12 weeks prior to enrolment or intention to change smoking status between enrolment and end of follow-up.
  20. Any clinically significant abnormal findings in physical examination, vital signs, , or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Tozorakimab

    Dosing subcutaneously tozorakimab

    Drug: Tozorakimab

  • Placebo comparator
    Placebo

    Dosing subcutaneously with equivalent volume to tozorakimab

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study

  • Administered subcutaneously tozorakimab and placebo throughout the study

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic

    The difference in mean change from baseline in FEV1

    Time frame: Baseline through Week 12

Secondary outcomes

  1. Annualized rate of composite endpoint for exacerbations in COPD (COPDCompEx) events

    The rate ratio of COPDCopmEx events

    Time frame: From baseline to Week 12

  2. Change from baseline in post-BD FEV1

    The difference in mean change from baseline in post-BD FEV1

    Time frame: From baseline through Week 12

  3. Change from baseline in pre-BD and post-BD forced vital capacity (FVC)

    The difference in mean change from baseline in pre-BD and post-BD FVC

    Time frame: From baseline through Week 12

  4. FEV1 % reversibility dynamics

    The difference in mean change from baseline in FEV1 % reversibility

    Time frame: From baseline to Week 12

  5. Change from baseline in peak expiratory flow (PEF) measured in clinic and at home

    The difference in mean change from baseline in PEF

    Time frame: From baseline through Week 12

  6. Change from baseline in home FEV1

    The difference in mean change from baseline in FEV1

    Time frame: From baseline through Week 12

  7. Time to first COPDCompEx event

    The hazard ratio for COPDCompEx event occurrence

    Time frame: From baseline to Week 12

  8. Change from baseline in mean Breathless, cough and sputum scale (BCSS) score

    The difference in mean change from baseline in BCSS. The BCSS, is a 3-item daily Diary that assesses the severity of the 3 symptoms: breathlessness, sputum, and cough; each on a 5-point scale (from 0 to 4). Higher scores for each domain, and thus for total score, indicate more severe symptoms.

    Time frame: From baseline to Week 12

  9. Change from baseline in COPD assessment test (CAT) total score

    The difference in mean change from baseline in CAT. The CAT consists of eight questions that ask the participant to rate items relating to symptoms and impact on quality of life (such as normal activity and sleep). Each question is performed on a scale from 0 to 5 with 0 being the best possible health status or least impairment and 5 being the worst health status or greatest impairment.

    Time frame: From baseline to Week 12

Other outcomes

  1. Number of patients with adverse events (AEs)

    The measure of interest is frequencies and percentages of participants with reported AEs.

    Time frame: Through study completion, up to 27 weeks

07

Study locations

12 sites
  • Research Site
    Aramil, 624002, Russia
  • Research Site
    Izhevsk, 426061, Russia
  • Research Site
    Moscow, 105554, Russia
  • Research Site
    Moscow, 117546, Russia
  • Research Site
    Moscow, 119048, Russia
  • Research Site
    Moscow, 125284, Russia
  • Research Site
    Omsk, 644099, Russia
  • Research Site
    Penza, 440067, Russia
  • Research Site
    Perm, 614000, Russia
  • Research Site
    Saint Petersburg, 193231, Russia
  • Research Site
    Saratov, 410054, Russia
  • Research Site
    Ulyanovsk, 432009, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at : https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Apr 2026, 12 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 12 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 27, 2025
StartActual
Apr 12, 2025
Primary completionActual
Apr 21, 2026
CompletionActual
Apr 21, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897748
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Apr 12, 2025
Primary completion
Apr 21, 2026
Completion
Apr 21, 2026
Last update
Jul 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion